BCL9 and neoplasm: We found that CD155/PVR-CD226 signaling occurs through VAV1 phosphorylation and BCL9 inhibition promotes antibody-mediated PD-1 blockade via promoting cytotoxic CD8+ T cell tumor infiltration in mouse models.